Category Archives: Topics

Additional Foundayo Prescription Trends; Regeneron MFN Deal; Arrowhead Positive CHMP Opinion; Eversense 365 CGM Launches in EU

A series of cardiometabolic-related news items has been observed from Lilly, Regeneron, Arrowhead Pharmaceuticals, and Senseonics. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Roche and Sanofi Q1 ’26 Earnings; Topline Ph3 PIONEER TEENS Data; Hims & Hers Expands Integration to LillyDirect; Amgen Management Changes

A series of cardiometabolic-related news items has been observed from Roche, Novo Nordisk, Hims & Hers, Sanofi, and Amgen. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

CMS Delays Launch of Obesity BALANCE Model; Sanofi’s Tzield Receives Black Box Warning Following Pediatric Label Expansion; Beta Bionics Q1 ’26 Earnings; Pfizer’s Ecnoglutide Injection Available for Pre-Order in China

A series of cardiometabolic-related news items has been observed from CMS, Sanofi, Beta Bionics, and Pfizer. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Pfizer’s Andrew Baum to Depart at the End of 2026; Amazon Launches AOM Management Program; Dexcom Opens First OUS CGM Manufacturing Site; Kailera Closes IPO; BioAge Reports Additional Ph1 NLRP3i Data; Abbott Wins Preliminary Injunction Appeal Against Sinocare

A series of cardiometabolic-related news items has been observed from Pfizer, Amazon, Dexcom, Kailera Therapeutics, BioAge Labs, and Abbott. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

New Foundayo DTC Ad; Roche Shares New INN for CT-388; April CHMP Agenda

Three cardiometabolic-related news items have been observed: Lilly aired a new Foundayo DTC ad on social media platforms (view Reddit post); Roche’s CT-388 has been given the INN of enicepatide, which is reflected in two Ph2 studies (view CT.gov record; view CT.gov record); and the CHMP agenda for this month’s meeting (April 20-23) has been released (view here). Below, FENIX provides highlights and insights on the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Early Foundayo Prescription Trends; Kailera Announces IPO Pricing; AZ’s Partner Initiates Ph1 FIH Study of Monthly Dual Agonist; ViCentra Eliminates Waiting Period for Kailedo Patch Pump in Select EU Countries

A series of cardiometabolic-related news items has been observed from Lilly, Kailera Therapeutics, AstraZeneca/CSPC Pharmaceuticals, and ViCentra. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Lilly Shares ACHIEVE-4 Topline Data and Receives CNPV for Orforglipron in T2DM; Novo Initiates AMAZE 2; Pfizer and D&D Pharmatech Research Service Agreement; Abbott Q1 ’26 Earnings; Novartis Ph1 HF Study

A series of cardiometabolic-related news items has been observed from Lilly, Novo Nordisk, Pfizer, Abbott, and Novartis. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Regeneron Targets PNPLA3 for MASH; Aurigene and Alveus Extend Collaboration

Two cardiometabolic-related news items have been observed: Regeneron initiated a new Ph2 MASH study (view CT.gov record), and Aurigene is expanding its partnership with Alveus Therapeutics (view LinkedIn post). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Obesity Spotlight Series: 2026 to Set AZ’s Trajectory

In the tenth installment of FENIX’s Obesity Spotlight Series, FENIX has conducted a deep dive analysis of AstraZeneca’s current position in the obesity market. The analysis includes insights into AZ’s strategy to replace Farxiga revenue and how it is seemingly following Lilly’s obesity playbook.

This content is for Read Less members only.
Register

Already a member? Log in here

FDA Publishes Foundayo Letter of Approval; Novo Partners with OpenAI for AI Drug Development; Sana T1DM Collaboration; Corbus Doses Last Patient in Ph1 CB1 Study

A series of cardiometabolic-related news items has been observed from FDA/Lilly, Novo Nordisk, Sana Biotechnology, and Corbus Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here